By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegenRx 

Case Western Reserve University
10900 Euclid Avenue
Cleveland  Ohio  44106  U.S.A.
Phone: 216-444-5757 Fax:


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up

Collaborations

Center for Stem Cell and Regenerative Medicine  (CSCRM startup company) capitalizes on the induction of homing in stem cells to areas of myocardial injury by specific factors.





Company News
U.S. Patent Office Significantly Extends The Term Of Three RegenRx Patents 11/3/2014 9:18:43 AM
RegenRx Issues $225,000 Convertible Note 4/1/2013 10:11:26 AM
RegenRx Release: New Data on Thymosin Beta 4 Reported at Third International Symposium on Thymosins in Health and Disease 3/20/2012 6:41:09 AM
RegenRx Issued Major U.S. Heart Patent 1/9/2012 6:50:45 AM
RegenRx Answers Questions Regarding Phase 2 Dry Eye Trial 11/4/2011 8:46:44 AM
RegenRx Reports New Statistically Significant Data Confirming Repair of Corneal Damage in Dry Eye Model 4/13/2011 8:29:42 AM
RegenRx: Two New Research Papers Published on Thymosin Beta 4 10/26/2007 10:15:45 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Study Confirms TB4 Improves Cardiovascular Function After Heart Attack; Collaboration With Pharmaceutical Firm Reproduces And Extends Findings Originally Published In Nature 9/11/2006 10:08:16 AM
//-->